secwatch / observer
8-K filed September 17, 2025, 7:59 PM ET CIK 0001888012
M&A confidence high sentiment neutral materiality 0.95

HilleVax, Inc.: M&A transaction — HilleVax acquired by XOMA Royalty for $1.95/share plus CVR; delisted from Nasdaq

HilleVax, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

HilleVax, Inc.: Certificate of incorporation amended and restated in its entirety in connection with merger (effective 2025-09-17).

Change
charter amendment
Effective
2025-09-17
Exact text from the filing
on September 17, 2025, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety and became the certificate of incorporation and bylaws of the Surviving Corporation.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

HilleVax, Inc.: Bylaws amended and restated in their entirety in connection with merger (effective 2025-09-17).

Change
bylaw amendment
Effective
2025-09-17
Exact text from the filing
on September 17, 2025, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety and became the certificate of incorporation and bylaws of the Surviving Corporation.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

HilleVax, Inc. underwent a change of control involving XOMA Royalty Corporation (Parent) and its wholly-owned subsidiary XRA 4 Corp. (Merger Sub) for $1.95 in cash per Share plus one non-transferable contractual contingent value right (closed 2025-09-17).

Action
change of control
Counterparty
XOMA Royalty Corporation (Parent) and its wholly-owned subsidiary XRA 4 Corp. (Merger Sub)
Consideration
$1.95 in cash per Share plus one non-transferable contractual contingent value right
Closing
2025-09-17
Exact text from the filing
a tender offer (the “Offer”) to acquire any and all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), for (i) $1.95 in cash per Share, payable without interest (the “Cash Amount”), plus (ii) one non-transferable contractual contingent value right (each, a “CVR”) per Share, representing the
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001193125-25-205570
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.